Successful Treatment with Intravenous Cyclophosphamide for Refractory Adult-Onset Still's Disease

Case Reports in Rheumatology
Yoshika TsujiKiyoshi Migita

Abstract

We report a 64-year-old female case of intractable adult-onset Still's disease (AOSD). Initial high-dose steroid therapy combined with cyclosporin A was ineffective against macrophage-activation syndrome (MAS), which was accompanied by the systemic type of AOSD. Treatment for MAS with intravenous cyclophosphamide resulted in remission of AOSD and a reduction in the high doses of steroids. Efficacy of biologics against MAS in AOSD is unclear. Cyclophosphamide, a conventional cytotoxic agent, should be considered as one of the therapeutic options for refractory types of AOSD with MAS.

References

Oct 13, 2005·Annals of the Rheumatic Diseases·P EfthimiouL Bielory
Aug 29, 2006·Pediatric Blood & Cancer·Jan-Inge HenterGritta Janka
Sep 5, 2006·Seminars in Arthritis and Rheumatism·Petros Efthimiou, Sharon Georgy
Oct 9, 2012·Best Practice & Research. Clinical Rheumatology·Jacques Pouchot, Jean-Benoît Arlet
Apr 13, 2013·British Journal of Haematology·G Naheed UsmaniPeter E Newburger
Jul 19, 2013·Rheumatology·Ibrahim A Al-Homood
Mar 25, 2014·Autoimmunity Reviews·Mathieu Gerfaud-ValentinPascal Sève
Apr 24, 2014·Arthritis & Rheumatology·Shunichi Kumakura, Yohko Murakawa
Sep 4, 2014·Autoimmunity Reviews·Alexandre Thibault Jacques MariaPhilippe Guilpain

❮ Previous
Next ❯

Related Concepts

Related Feeds

Adult-Onset Still's Disease

Adult-onset Still's disease (AOSD) is a form of Still's disease, a rare systemic autoinflammatory disease characterized by the classic triad of persistent high spiking fevers, joint pain, and a distinctive salmon-colored bumpy rash. Discover the latest research on AOSD here.